amangelrti.org
919-485-5668
Research Triangle Park, NC

Allen W. Mangel

Expertise

Gastroenterology
Clinical Development

Biography

Allen Mangel, MD, PhD, is a gastroenterologist and senior vice president of RTI Health Solutions. After his medical training, Dr. Mangel was an intern and resident in internal medicine at Duke University Medical Center and also completed his gastroenterology fellowship at Duke. After this formal training, he remained on the Duke faculty in the Department of Medicine, Division of Gastroenterology. After leaving Duke, he joined the gastroenterology clinical research department at Glaxo Wellcome, where he was head of the gastroenterology clinical development group. Following Glaxo, Dr. Mangel became vice president of research and development at Salix Pharmaceuticals. Dr. Mangel also has a PhD from the University of Illinois, where his research focused on control of electrical and mechanical activity in gastrointestinal smooth muscle. He has led or participated in numerous FDA interactions, Advisory Committee presentations, label negotiations, and NDA submissions, and he has written over 85 publications.

Education

MD, Georgetown University School of Medicine; PhD, Physiology, University of Illinois; MS, Physiology, University of Illinois; BS, Physiology, University of Illinois.

Selected Publications

Camilleri, M., Mangel, A.W., Fehnel, S.E., Drossman, D.A., Mayer, E.A., & Talley, N.J. (May 2007). Primary endpoints for irritable bowel syndrome trials: A review of performance of endpoints. Clinical Gastroenterology and Hepatology, 5 (5):534-40.

Mangel, A.W. (Apr 2006). Personal view: adequate relief as a primary endpoint in irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 23 (7):879-881.

Williams, R., Black, C., Kim, H., Andrews, E.B., Mangel, A.W., Buda, J.J., & Cook, S.F. (Jan 2006). Stability of irritable bowel syndrome using a Rome II-based classification. Alimentary Pharmacology and Therapeutics, 23 (1):197-205.

Andrews, E.B., Eaton, S.C., Hollis, K.A., Hopkins, J.S., Ameen, V.Z., Hamm, L.R., Mangel, A.W., Tennis, P., & Cook, S.F. (2005). Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Alimentary Pharmacology and Therapeutics, 2005 (22):935-942.

Camilleri, M., Chey, W.Y., Mayer, E.A., Northcutt, A.R., Heath, A., Dukes, G.E., McSorley, D., & Mangel, A.W. (2001 Jul 23). A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Archives of Internal Medicine, 161 (14):1733-1740.

Mangel, A.W., Scott, L., Prpic, V., & Liddle, R.A. (1996 Oct). Regulation of cholecystokinin secretion in STC-1 cells by nitric oxide.. American Journal of Physiology. Gastrointestinal and Liver Physiology, 271 (4):G650-654.

Mangel, A.W. (April 1995). Electrophysiology of intestinal cholecystokinin secretion. Regulatory Peptides , 56 (2-3):121-129.

Mangel, A.W., Fahimi, M., & van Breemen, C. (26 March 1982). Control of vascular contractility by the cardiac pacemaker. Science, 215 (4540):1627-1629.

Mangel, A.W., Nelson, D.O., Connor, J.A., & Prosser, C.L. (18 Oct 1979). Contractions of cat small intestinal smooth muscle in calcium-free solution. Nature, 281 (5732):582-583.

View all publications by Allen W. Mangel…